Why predictive intelligence is changing the Medical Science Liaison model

Tern plc

Medical Science Liaisons have traditionally been the scientific connection between pharmaceutical companies and healthcare professionals. Their role is centred on non promotional dialogue, explaining clinical evidence, answering scientific questions and collecting feedback from the field. For many years this model relied on structured engagement plans, established opinion leaders and scheduled interactions at congresses or advisory boards.

However, the information environment surrounding modern healthcare has changed significantly. Scientific debate now develops continuously across digital platforms, academic publications and professional networks. Clinicians discuss emerging evidence faster and across more channels than before.

The challenge for Medical Affairs teams is not simply operational. Pharmaceutical companies increasingly rely on Medical Affairs to provide early visibility on shifts in clinical thinking, treatment behaviour and emerging scientific questions. If insight from the field arrives too slowly, the organisation may miss early signals that influence how therapies are positioned, studied or adopted in practice.

Traditional MSL planning typically focuses on a fixed group of recognised experts. While these relationships remain valuable, influence in healthcare conversations is now more fluid. New voices often emerge quickly around specific research topics, clinical questions or therapeutic developments. Identifying these individuals early can be important for companies seeking to understand how medical narratives are evolving.

Predictive intelligence offers a way to address this gap. By analysing large volumes of healthcare discussion, scientific publication activity and other behavioural signals, data models can identify patterns that indicate where medical conversations are forming and who is shaping them. This allows Medical Affairs teams to prioritise engagement based on current influence rather than relying solely on historical relationships.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search